Biotech financing is beginning to rebound, but not across the board. According to June 2025 data, public biotech fundraising surpassed private for the first time this year, totaling $2.7 billion. But a closer look reveals a consistent theme, capital is flowing to companies with clear commercialization strategies, clinical milestone momentum, and operational readiness.
This shift marks a decisive departure from the high-risk appetite of 2021. Today, institutional capital is seeking de-risked programs and confident execution. At Orchestra Life Sciences, we help our clients align with these expectations through strategic, technical, and regulatory support tailored for radiopharmaceuticals and advanced therapies.
The 2025 Funding Landscape: What Investors Want
June’s top funding rounds demonstrate that investors are backing companies that are built to deliver:
- Insmed raised $750M in a public offering to support R&D and commercialization activities for its lead pulmonary candidate, brensocatib.
- Cidara Therapeutics secured $402.5M and Merus brought in $300M, both from public offerings tied to clinical and commercial advancement.
- Cogent Biosciences obtained $400M in non-dilutive financing, with staged access based on topline trial data and early commercial performance.
- Dyne Therapeutics closed a $275M term loan facility to fund development through critical clinical and regulatory milestones.
Capital is available, but it’s being deployed with precision. Companies must be prepared to show credible execution plans tied to regulatory, manufacturing, and commercial progress.
What This Means for Biotechs
The days of speculative platform funding are behind us. Instead, investors are rewarding companies that can demonstrate:
- A defined path to commercialization
- Regulatory alignment and milestone-based planning
- Manufacturing scalability with GMP compliance
- Operational de-risking through credible execution partners
- Cross-functional expertise in complex modalities like radiopharma and CGT
These are exactly the areas where Orchestra Life Sciences delivers measurable value and map directly to what today’s capital markets reward:
Defined Commercialization Strategy
We support clients in building commercialization roadmaps from IND to launch, including facility readiness planning and strategic scale-up initiatives.
Regulatory and GMP Manufacturing Readiness
We specialize in facility design, qualification, and regulatory execution, helping clients become inspection-ready and milestone-aligned.
Operational De-Risking
Orchestra leads end-to-end vendor, supplier, and partner management, giving companies the predictable timelines and outcomes required to unlock milestone-based or non-dilutive capital.
Radiopharma and CGT Expertise
Our team understands the technical nuance of isotope production, complex biologic handling, and integrated supply chains, providing reassurance to investors that scientific innovation is backed by operational strength.
Credibility Through Strategic Networks
We work with trusted partners across the ecosystem and have supported successful M&A transactions.
Positioning Your Program for Capital in 2025
Whether you’re preparing for a Series A, seeking non-dilutive capital, or aiming for public markets, being investor-ready means being execution-ready. At Orchestra, we help clients:
- Translate scientific vision into actionable technical plans
- Design and qualify GMP facilities
- Navigate regulatory pathways with confidence
- Secure supply chain resilience
- Develop scalable infrastructure for launch
As June’s data suggests, biotech capital is making a rebound, but the investors of 2025 are betting on execution. With Orchestra Life Sciences, you gain more than a consultancy, you gain a strategic partner built to deliver on time, on target.
Explore how we can work with the experts for the experts to help position your program for success: orchestralifesciences.com